NanoString Developing Genomic Test to Gauge Benefit of Chemo Classes for Breast Cancer

NanoString is betting that its test will predict treatment benefit for specific classes of chemotherapies, which will differentiate it from other genomic breast cancer tests on the market.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.